Literature DB >> 17194493

Clinical experience of MEK inhibitors in cancer therapy.

Ding Wang1, Scott A Boerner, James D Winkler, Patricia M LoRusso.   

Abstract

Finding new therapies to assist in the treatment of cancer is a major challenge of clinical research. Small molecules that inhibit different molecular targets at the different levels of the MAPK pathway have been developed. Several MEK inhibitors have been examined in early-phase clinical trials and the current state of clinical results using these therapies is presented here.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17194493     DOI： 10.1016/j.bbamcr.2006.11.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  69 in total

1.  Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Authors:  John J Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M Pitts; M Pia Morelli; Heather M Selby; Maria I Kachaeva; Sara A Flanigan; Gillian N Kulikowski; Stephen Leong; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2010-10-05       Impact factor: 6.261

2.  MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

Authors:  L Maubon; N Hirji; R Petrarca; P Ursell
Journal:  Eye (Lond)       Date:  2015-11-20       Impact factor: 3.775

3.  Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells.

Authors:  Rina Gendelman; Heming Xing; Olga K Mirzoeva; Preeti Sarde; Christina Curtis; Heidi S Feiler; Paul McDonagh; Joe W Gray; Iya Khalil; W Michael Korn
Journal:  Cancer Res       Date:  2017-01-13       Impact factor: 12.701

4.  KB-Rank: efficient protein structure and functional annotation identification via text query.

Authors:  Elchin S Julfayev; Ryan J McLaughlin; Yi-Ping Tao; William A McLaughlin
Journal:  J Struct Funct Genomics       Date:  2012-01-21

5.  KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Authors:  Jen Jen Yeh; Elizabeth D Routh; Tara Rubinas; Janie Peacock; Timothy D Martin; Xiang Jun Shen; Robert S Sandler; Hong Jin Kim; Temitope O Keku; Channing J Der
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

6.  P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Authors:  Yosi Shamay; Moshe Elkabets; Hongyan Li; Janki Shah; Samuel Brook; Feng Wang; Keren Adler; Emily Baut; Maurizio Scaltriti; Prakrit V Jena; Eric E Gardner; John T Poirier; Charles M Rudin; José Baselga; Adriana Haimovitz-Friedman; Daniel A Heller
Journal:  Sci Transl Med       Date:  2016-06-29       Impact factor: 17.956

Review 7.  Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.

Authors:  Christine A Pratilas; David B Solit
Journal:  Clin Cancer Res       Date:  2010-05-14       Impact factor: 12.531

8.  The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines.

Authors:  Katarina Matkovic; Vesna Lukinovic-Skudar; Hrvoje Banfic; Dora Visnjic
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

9.  MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Authors:  Shaofang Wu; Shuzhen Wang; Siyuan Zheng; Roel Verhaak; Dimpy Koul; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2016-04-22       Impact factor: 6.261

10.  High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).

Authors:  Jieru Meng; Henry Peng; Bingbing Dai; Wei Guo; Li Wang; Lin Ji; John D Minna; Christine M Chresta; Paul D Smith; Bingliang Fang; Jack A Roth
Journal:  Cancer Biol Ther       Date:  2009-11-18       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.